Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · BIODESIX INC (BDSX)

Biodesix Chief Commercial Officer Kieran O'Kane's employment ends November 2, 2026

Neutral Impact 3 of 5 leadership Written later

Biodesix said the employment of Chief Commercial Officer Kieran O'Kane ends effective November 2, 2026. He is eligible for separation benefits under his existing Executive Severance and Change in Control Agreement, based on a qualifying termination.

Key points

  • Kieran O'Kane, Chief Commercial Officer, departs effective November 2, 2026, the agreed Separation Date.
  • Separation benefits are available under his existing Executive Severance and Change in Control Agreement, as described in the 2026 proxy statement filed April 9, 2026.
  • The filing does not state the dollar value of the separation benefits or name a replacement.

The filing

CompanyBIODESIX INC (BDSX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:08 PM ET
Accession number0001193125-26-449792

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.